Adaptimmune Limited Company Profile
Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy cancerous or infected cells. Established in July 2008, Adaptimmune was set up to develop Immunocore Ltd’s (formerly Avidex/MediGeneLtd’s) unique T cell receptor engineering technology for adoptive T cell therapy.
Specifically, Adaptimmune makes use of the body’s ability to recognize infected or cancerous cells by enhancing the power of the T cell receptor (TCR) on killer T cells.
Cancerous or virally infected cells will typically present small parts or peptides of larger viral proteins or abnormal cancer proteins on their surface, offering a "molecular fingerprint", called an epitope, for killer T-cells from the immune system to identify. In a healthy individual, this triggers an immune response, eliminating the affected cell. However, viruses such as HIV mutate rapidly, swiftly disguising their fingerprints to allow them to hide from killer T-cells while cancer proteins are usually derived from self-proteins against which natural TCRs do not respond. Adaptimmune’s technology uniquely enhances the natural TCR affinity to either viral or cancer protein epitopes on an individual patient’s cells overcoming these obstacles for therapeutic benefit.
Adaptimmune has undertaken significant preclinical development with a number of pipeline TCRs to demonstrate their potency and specificity in vitro. The TCRs in the current ovarian study are specific to the cancer testis antigen targets NY-ESO-1 157-165 (HLA A2; SLLMWITQC) and was engineered using Adaptimmune’s proprietary TCR engineering platform. It is poised to gather clinical safety and efficacy data on these and other TCRs with regulatory approvals for human trials in HIV and multiple cancers now in place.
57 Jubilee Avenue
Phone: +44 (0) 1235 438642
Fax: +44 (0) 1235 438607
The U.K.'s Biomedical Catalyst Fund has awarded $3.5 million to Adaptimmune to expedite the development of the company's seco -More-
Biotech firm Adaptimmune has been awarded £2.1 million from the UK government’s Biomedical Catalyst Fund, which was set up to push forward translational research. The £180 million fund, managed by...
Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical R...
20 November, 2013: Oxford, U.K & Philadelphia, U.S — Adaptimmune, the T cell therapy company pioneering engineered T cell receptors for the treatment of cancer and infectious disease, ...
25 March 2014: Oxford, UK and Philadelphia, USA - Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK's ...
Adaptimmune has received £2.1m grant from the Biomedical Catalyst Fund to advance the development of company’s second engineered T cell therapy program into the clinic in triple negative breast can...
26 March 2014: Oxford, UK & Philadelphia, USA - Adaptimmune Ltd, the biotechnology company focused on the use of engineered T cells to treat cancer, announces the full-time appointment of ...
UK-headquartered biotechnology firm Adaptimmune has reported encouraging early stage results for its T-cell receptor (TCR) technology in multiple myeloma – highlighting promising response rates,...
Drugs and Medications
Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy can...
Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located...
More Information about "Adaptimmune Limited" on BioPortfolio
We have published hundreds of Adaptimmune Limited news stories on BioPortfolio along with dozens of Adaptimmune Limited Clinical Trials and PubMed Articles about Adaptimmune Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Adaptimmune Limited Companies in our database. You can also find out about relevant Adaptimmune Limited Drugs and Medications on this site too.